<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03168724</url>
  </required_header>
  <id_info>
    <org_study_id>MUHC-16-031</org_study_id>
    <nct_id>NCT03168724</nct_id>
  </id_info>
  <brief_title>Goal Management Training, Executive Functions and HIV</brief_title>
  <official_title>Efficacy Potential of Goal Management Training to Improve Cognitive Function in Older People Living With HIV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McGill University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Goal Management Training (GMT) is a cognitive rehabilitation program targeting executive&#xD;
      dysfunction (problems with attention, reasoning, problem solving, planning, etc), which is a&#xD;
      central problem in HIV-associated neurocognitive disorder. It teaches self-management&#xD;
      principles, stress management and mindfulness, and trains participants in the use of several&#xD;
      strategies to reduce cognitive load in everyday tasks, and methods to cue attention to&#xD;
      maintain focus on specific tasks. GMT is a manualized protocol with set content conveyed&#xD;
      through a combination of slides and a workbook. Two-hour small group sessions are led, in&#xD;
      person, by a trained therapist once a week, for nine weeks. The small group sessions allow&#xD;
      participants to learn from each other, enhancing engagement. GMT has been shown to improve&#xD;
      cognitive function in a variety of neurological conditions, as well as in healthy older&#xD;
      people with cognitive concerns. These improvements have been shown to last at least 6 months&#xD;
      in some studies and are accompanied by changes in the brain networks underlying executive&#xD;
      function. GMT is thus a well-validated, high yield intervention with which to test the&#xD;
      potential of cognitive rehabilitation in older HIV+ people with cognitive concerns.&#xD;
&#xD;
      The researchers hypothesize that GMT will lead to improved cognitive function as assessed by&#xD;
      better performance on cognitive tests and reduced self-reported cognitive difficulties in&#xD;
      people with stable HIV infection who report cognitive difficulties at baseline.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rehabilitation is a well-established approach to maintain function in the face of chronic&#xD;
      disease, and holds promise for addressing the health challenges faced by older people with&#xD;
      HIV. A Canadian-led knowledge synthesis review published in 2014 identified cognitive&#xD;
      rehabilitation as a promising approach in HIV, but highlighted the absence of high quality,&#xD;
      HIV-specific evidence in this area. A recent focused review also highlights the dearth of&#xD;
      evidence on this topic. Very few studies have been published, and to date all have been&#xD;
      restricted to computerized training programs only. While there is limited evidence for&#xD;
      computerized cognitive rehabilitation in any context, there is better evidence for more&#xD;
      conventional, in-person rehabilitation approaches, at least in other neurological disorders.&#xD;
      Although computerized training is appealing because it is more feasible to deliver on a wide&#xD;
      scale than conventional cognitive rehabilitation, The researchers propose that the first step&#xD;
      should be to establish an evidence base regarding the efficacy of any form of cognitive&#xD;
      rehabilitation in HIV. Evidence of efficacy of a 'high dose' established rehabilitation&#xD;
      method could be followed by work to define the key elements, and to study how those elements&#xD;
      could be delivered most cost-effectively, but there is no point in pursuing these secondary&#xD;
      steps if the most well-established cognitive rehabilitation approaches do not show efficacy.&#xD;
      Thus, the researchers propose to test conventional rehabilitation as a crucial first step is&#xD;
      a research program focused on evidence-based interventions for improving brain health in HIV.&#xD;
&#xD;
      There is no gold standard conventional cognitive rehabilitation program, but most existing&#xD;
      approaches combine face-to-face therapy with at home practice over a period of at least&#xD;
      several weeks. In the absence of a gold standard, the researchers have selected one such&#xD;
      program: Goal Management Training (GMT). This program targets executive dysfunction, which is&#xD;
      a central problem in HIV-associated neurocognitive disorder. GMT is grounded in a&#xD;
      neurobiological framework and was developed based on nearly two decades of research on&#xD;
      practical approaches to minimizing the impact of executive dysfunction, aiming to help people&#xD;
      with brain injury manage real life tasks. The program teaches self-management principles,&#xD;
      stress management and mindfulness, and trains participants in the use of several explicit&#xD;
      strategies to reduce cognitive load in everyday tasks, and methods to cue attention to&#xD;
      maintain focus on specific tasks. GMT is a manualized protocol with set content conveyed&#xD;
      through a combination of slides and a workbook. Two-hour small group sessions are led, in&#xD;
      person, by a trained therapist once a week, for seven weeks. The small group sessions allow&#xD;
      participants to learn from each other, enhancing engagement. GMT has been shown to improve&#xD;
      cognitive function in a variety of neurological conditions, as well as in healthy older&#xD;
      people with cognitive concerns. Evidence from randomized trials shows that this intervention&#xD;
      leads to (i) significant improvements in performance on cognitive tests, including&#xD;
      naturalistic tests of real life tasks, (ii) reduced self-reported cognitive difficulties, and&#xD;
      (iii) significant improvements in everyday function compared to either a wait-list condition&#xD;
      or a general brain health education control. Positive effects have been found in older people&#xD;
      with cognitive difficulties, and neurological populations with mild cognitive impairment&#xD;
      including mild traumatic brain injury, stroke and spina bifida. These improvements have been&#xD;
      shown to last at least 6 months in some studies and are accompanied by changes in the brain&#xD;
      networks underlying executive function. GMT is thus a well-validated, high yield intervention&#xD;
      with which to test the potential of cognitive rehabilitation in older HIV+ people with&#xD;
      cognitive concerns.&#xD;
&#xD;
      The pilot project is nested within an ongoing observational cohort study that aims to&#xD;
      understand and address the heterogeneous, multi-factorial nature of compromised brain health&#xD;
      in people living with HIV. Study participants will be randomly selected from those&#xD;
      participating in the ongoing, longitudinal Positive Brain Health Now (+BHN) study at 2 sites&#xD;
      in Montreal (The Montreal Chest Institute and L'Actuel Medical Clinic). This CIHR Team&#xD;
      Grant-supported observational, prospective cohort study has enrolled 840 consecutive patients&#xD;
      attending 5 HIV clinics across Canada, who are followed every 9 months for 27 months.&#xD;
&#xD;
      Procedure Participants will be recruited either at the time of their routine +BHN study&#xD;
      visit, or by phone or by email. Informed consent will occur with the therapist during the&#xD;
      first GMT group session during which they will also complete a questionnaire regarding any&#xD;
      cognitive concerns they may have (Communicating Cognitive Concerns-C3Q). At the end of the&#xD;
      last GMT session, they will be asked to complete the C3Q again. Then, within 4 weeks of&#xD;
      completing the GMT program, they will be asked to repeat the B-CAM, coincident with the +BHN&#xD;
      study visit if timing permits.&#xD;
&#xD;
      Intervention The standard GMT program lasts 9 weeks and involves 9 weekly 2-hour small group&#xD;
      sessions led by a trained therapist. It follows a manualized program that teaches&#xD;
      participants a series of techniques to build attention and executive function, and shows them&#xD;
      how to implement these techniques in their everyday life. The small group sessions allow&#xD;
      individualization of the training to show how it can be applied to meet the particular&#xD;
      challenges reported by participants, and explicitly encourage participants to share their&#xD;
      challenges and successes with others in the group to promote learning and engagement with the&#xD;
      program. The sessions are reinforced with homework, in which participants practice what they&#xD;
      have learned. Sessions will be audiotaped for later review by the trainer and/or study&#xD;
      investigators to ensure adherence to the intervention manual. The material, including&#xD;
      homework, is provided in a workbook that participants use throughout the training, and keep&#xD;
      for later reference.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Actual">August 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Performance measure (B-CAM)</measure>
    <time_frame>Up to 9 months before the intervention and up to 2 months after the intervention</time_frame>
    <description>We will be looking at changes on the B-CAM (brief cognitive ability measure) pre- and post-intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tower of London (cognitive outcome measure)</measure>
    <time_frame>Up to 9 months before the intervention and up to 2 months after the intervention</time_frame>
    <description>Assesses planning and mental flexibility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Communicating Cognitive Concerns (C3Q)</measure>
    <time_frame>On the first day of the intervention and 9 weeks after the beginning of the intervention</time_frame>
    <description>Evaluates cognitive concerns participants may have</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hiv</condition>
  <arm_group>
    <arm_group_label>GMT Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Over the course of 9 weeks, there are 2h-group sessions with a therapist.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Group not getting the intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>GMT intervention</intervention_name>
    <arm_group_label>GMT Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV infection for at least 1 year&#xD;
&#xD;
          -  Able to communicate in French or English&#xD;
&#xD;
          -  Capable of providing informed consent&#xD;
&#xD;
          -  Over 45 years old&#xD;
&#xD;
          -  Subjective cognitive complaints&#xD;
&#xD;
          -  Performance on objective computerized cognitive tests that falss at or below 50th&#xD;
             percentile of performance in the cohort (main study) as a whole)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of dementia&#xD;
&#xD;
          -  Life expectancy of 3 years or less&#xD;
&#xD;
          -  Other neurological disorder including opportunistic CNS infection, psychotic disorder&#xD;
&#xD;
          -  Current substance dependence or abuse&#xD;
&#xD;
          -  Hepatitis C requiring interferon therapy during the study period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>46 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Josee Brouillette, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University Health Centre/Research Institute of the McGill University Health Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lesley Fellows, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinique Medicale L'Actuel</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 28, 2017</study_first_submitted>
  <study_first_submitted_qc>May 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2017</study_first_posted>
  <last_update_submitted>September 1, 2020</last_update_submitted>
  <last_update_submitted_qc>September 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McGill University</investigator_affiliation>
    <investigator_full_name>Marie-Jos√©e Brouillette</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Cognition</keyword>
  <keyword>Intervention</keyword>
  <keyword>Self-management</keyword>
  <keyword>Rehabilitation</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 7, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/24/NCT03168724/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

